Is dopamine agonist therapy associated with developing pathological gambling in Parkinson's disease patients?
In recent years, improving the quality of life and the level of functioning in Parkinson's disease patients has become the main challenge of all therapeutic protocols for this chronic disease. Hence, identifying comorbid psychiatric conditions is the ambition of many studies in the field. To date, a few research studies have investigated the development of problem gambling as a potential side effect of dopamine agonist medications. However, there are still controversies among experts in the field. Thus far, published reports have been able to neither demonstrate the extent of risk for gambling-related problems nor study the correlation of dosage with this potential adverse effect among Parkinson's disease patients treated with dopaminergic medications. In fact, prospective epidemiologic studies are needed to technically estimate the incidence rate and the relative risk of pathological gambling among patients with Parkinson's disease and to determine the correlation between dosage of these medications and the development of pathological gambling.
Zand
Ramin
R
The International Institute of Health Studies, Ottawa, Ont., Canada. zand@iihs.ca
D007174:Disruptive, Impulse Control, and Conduct Disorders / Q000139:chemically induced*; D018491:Dopamine Agonists / Q000009:adverse effects*; D005715:Gambling; D006801:Humans; D010300:Parkinson Disease / Q000188:drug therapy
D018491:Dopamine Agonists